Main Article Content
Purpose: To determine the effect of carboprost tromethamine and carbetocin on coagulation factors and prognosis in puerpera with postpartum hemorrhage due to uterine inertia.
Methods: A total of 80 high-risk pregnant women with postpartum hemorrhage due to uterine inertia admitted to Longyan First Hospital Affiliated of Fujian Medical University, Longyan, China from June 2021 to June 2022 were randomly divided into control group (oxytocin + carboprost tromethamine, n = 40) and study group (oxytocin + carboprost tromethamine + carbetocin, n = 40). Vaginal bleeding volume was recorded for both groups at delivery, and 2 and 24 h after delivery. Decrease in hemoglobin level 24 h after delivery, as well as levels of coagulation factors, and adverse drug reactions before and after treatment were assessed.
Results: The third stage of labor, postpartum hemorrhage at 2 and 24 h, and decrease in hemoglobin 24 h after delivery in the study group were lower (p < 0.05). Compared with that before treatment, PLT and FIB levels also fell, while APTT and PT levels rose in both groups after treatment for 24 h (p < 0.05). Platelet count and fibrinogen levels in the study group were lower after treatment for 24 h, but APTT and PT levels were higher (p < 0.05). There was no statistically significant difference in the incidence of adverse drug reactions between both groups (15.00 vs 12.50 %; p > 0.05).
Conclusion: Co-administration of carboprost tromethamine with carbetocin prevents high-risk postpartum hemorrhage in pregnant women due to uterine inertia. It also reduces the level of bleeding, and promotes recovery of coagulation function. However, further clinical trials on a larger scale are recommended prior to the application of this treatment strategy in clinical practice.